O-1663

O-1663 is a full agonist of cannabinoid receptor 2 (CB2 receptor). O-1663 stimulates the production of ROS, downregulates Id1, and induces autophagy and apoptosis in breast cancer cells. O-1663 inhibits the proliferation, invasion and metastasis of breast cancer cells. O-1663 prolongs the survival of models with advanced metastatic breast cancer. O-1663 can be used for the research of metastatic breast cancer^[1]. In Vitro:O-1663 (1-4 μM; 2 days) potently inhibits the proliferation/survival of human MDA-MB231 and 4T1 breast cancer cells, with IC₅₀ values of 0.85 μM and 0.83 μM, respectively. This effect is partially mediated by CB2 receptor activation and ROS production^[1].
O-1663 (1 μM; 3 days) potently inhibits the invasion of human MDA-MB231 breast cancer cells, with an IC₅₀ of 0.6 μM^[1].
O-1663 inhibits the proliferation and viability of human MDA-MB231-luc-D3H2LN breast cancer cells, with an IC₅₀ value of 1.0 μM^[1].
O-1663 (1-1.5 μM; 2-3 days) downregulates Id1 expression and upregulates Id2 expression in human MDA-MB231 and mouse 4T1 breast cancer cells, and also stimulates autophagy in MDA-MB231 cells by upregulating LC3-II expression to a level comparable to that of THC^[1].
O-1663 (0.5-1.5 μM; 2 days) significantly induces ROS production in human MDA-MB231 breast cancer cells^[1].
O-1663 (1.5 μM; 2 days) induces apoptosis in human MDA-MB231 breast cancer cells^[1]. In Vivo:O-1663 (0.1-1 mg/kg; i.p.; once daily; for 14 consecutive days) potently inhibits breast cancer metastasis in BALB/c mice^[1].
O-1663 (0.5-1 mg/kg; i.p.; daily administration; for 6 consecutive weeks) potently inhibits the metastasis of human MDA-MB231 breast cancer cells in athymic nu/nu mice^[1].